Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AngioDynamics Inc ANGO

Healthcare Medical Devices
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the... see more

Recent & Breaking News (NDAQ:ANGO)

AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer

Business Wire February 6, 2020

AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON(TM) Atherectomy System

Business Wire January 16, 2020

Stock Futures Flat as Investors Weigh Geopolitical Risk

Livemoney January 7, 2020

AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results

Business Wire January 7, 2020

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Business Wire January 6, 2020

AngioDynamics to Report Fiscal 2020 Second Quarter Financial Results on January 7, 2020

Business Wire December 10, 2019

AngioDynamics Announces Departure of CFO and Appointment of Interim CFO

Business Wire October 22, 2019

AngioDynamics Reports Fiscal 2020 First Quarter Financial Results

Business Wire October 3, 2019

AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology

Business Wire October 3, 2019

AngioDynamics Awarded Premier's Nationally Outsourced Implantable Infusion Port Agreement

Business Wire September 9, 2019

AngioDynamics to Report Fiscal 2020 First Quarter Financial Results on October 3, 2019

Business Wire September 5, 2019

AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors

Business Wire July 31, 2019

AngioDynamics to Present at the Canaccord Genuity Growth Conference

Business Wire July 23, 2019

AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results

Business Wire July 10, 2019

AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019

Business Wire June 20, 2019

AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference

Business Wire June 4, 2019

AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.

Business Wire June 3, 2019

AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange

Business Wire May 28, 2019

AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

Business Wire May 22, 2019

AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

Business Wire May 13, 2019